个人中心 - 老虎社区

Jordern5665

IP属地：未知

帖子 · 7帖子 · 7
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- Jordern5665Jordern5665
  ·2021-07-01
  Thanks
  1,534 评论
  点赞
  分享
  举报
- Jordern5665Jordern5665
  ·2021-06-24
  Nice
  非常抱歉，此主贴已删除
  1,786 评论
  点赞
  分享
  举报
- Jordern5665Jordern5665
  ·2021-06-24
  Nice
  A 6.7-Inch iPhone At $900? Analyst Says Apple Will Bring This Product To Market Next Year<blockquote>售价900美元的6.7英寸iPhone？分析师称苹果将于明年将该产品推向市场</blockquote>
  Apple Inc(NASDAQ:AAPL) will launch two lower-end iPhones with larger screens next year, as per analy
  A 6.7-Inch iPhone At $900? Analyst Says Apple Will Bring This Product To Market Next Year<blockquote>售价900美元的6.7英寸iPhone？分析师称苹果将于明年将该产品推向市场</blockquote>
  1,291 评论
  1
  分享
  举报
- Jordern5665Jordern5665
  ·2021-06-24
  Apple is the best
  2,166 评论
  1
  分享
  举报
- Jordern5665Jordern5665
  ·2021-06-21
  Can invest this one ?
  Orphazyme rose more than 6% in premarket trading<blockquote>Orphazyme盘前交易涨超6%</blockquote>
  (June 21) Orphazyme rose more than 6% in premarket trading. What happened Shares of Orphazyme, a c
  Orphazyme rose more than 6% in premarket trading<blockquote>Orphazyme盘前交易涨超6%</blockquote>
  869 评论
  1
  分享
  举报
- Jordern5665Jordern5665
  ·2021-06-12
  [Cry]
  非常抱歉，此主贴已删除
  1,088 评论
  1
  分享
  举报
- Jordern5665Jordern5665
  ·2021-06-11
  [Cool]
  1,325 评论
  点赞
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3586338829912658","uuid":"3586338829912658","gmtCreate":1623247508144,"gmtModify":1623377522326,"name":"Jordern5665","pinyin":"jordern5665","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":8,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.16%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.58%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":151241265,"gmtCreate":1625096396357,"gmtModify":1631891683958,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586338829912658","idStr":"3586338829912658"},"themes":[],"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[{"img":"https://static.tigerbbs.com/d1cbb1a770832b5037394f9ae1894e5d","width":"750","height":"1238"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/151241265","isVote":1,"tweetType":1,"viewCount":1534,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":128455071,"gmtCreate":1624528879993,"gmtModify":1631891683966,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586338829912658","idStr":"3586338829912658"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128455071","repostId":"2145043969","repostType":4,"isVote":1,"tweetType":1,"viewCount":1786,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128456269,"gmtCreate":1624528839051,"gmtModify":1631891683978,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586338829912658","idStr":"3586338829912658"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128456269","repostId":"1184361611","repostType":4,"repost":{"id":"1184361611","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1624526066,"share":"https://www.laohu8.com/m/news/1184361611?lang=zh_CN&edition=full","pubTime":"2021-06-24 17:14","market":"us","language":"en","title":"A 6.7-Inch iPhone At $900? Analyst Says Apple Will Bring This Product To Market Next Year<blockquote>售价900美元的6.7英寸iPhone？分析师称苹果将于明年将该产品推向市场</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1184361611","media":"Benzinga","summary":"Apple Inc(NASDAQ:AAPL) will launch two lower-end iPhones with larger screens next year, as per analy","content":"<p><b>Apple Inc</b>(NASDAQ:AAPL) will launch two lower-end iPhones with larger screens next year, as per analyst Ming-Chi Kuo.</p><p><blockquote><b>苹果公司</b>据分析师郭明錤称，（纳斯达克：AAPL）将于明年推出两款屏幕更大的低端iPhone。</blockquote></p><p> <b>What Happened:</b>&nbsp;Apple’s lineup in the second half of 2022 will include two iPhone lines with 6.7-inch screens — one will&nbsp;serve the low-end market and another will cater to the premium one, Kuo said, as per9to5Mac.&nbsp;Both these models will also be available in the 6.1-inch screen size.</p><p><blockquote><b>发生了什么：</b>郭说，苹果在2022年下半年的产品阵容将包括两个6.7英寸屏幕的iPhone系列——一个将服务于低端市场，另一个将迎合高端市场，称为per9to5Mac。这两种型号也将提供6.1英寸的屏幕尺寸。</blockquote></p><p> According to the report, Kuo believes the 2022 lineup will have under-display fingerprint support and it will be available at the most affordable price point for a large screen and expected to be under $900.</p><p><blockquote>根据该报告，Kuo认为2022年的阵容将支持显示下指纹，它将以大屏幕最实惠的价格提供，预计将低于900美元。</blockquote></p><p> The current iPhone lineup includes the 6.7-inch iPhone 12 Pro Max, which is priced at $1,099. Kuo said the 2022 lineup could be named iPhone 14, iPhone 14 Pro, and iPhone 14 Pro Max.</p><p><blockquote>目前的iPhone阵容包括6.7英寸的iPhone 12 Pro Max，售价为1099美元。Kuo表示，2022年的产品阵容可能会被命名为iPhone 14、iPhone 14 Pro和iPhone 14 Pro Max。</blockquote></p><p> <b>Why It Matters:</b>&nbsp;Apple’s iPhone 12 Pro Max, launched last year, is its biggest phone to-date. The company’s yet-to-be-announced 2021 lineup is expected to sport the same variants as its predecessor from last year and the big changes will only be revealed next year, as per reports.</p><p><blockquote><b>为什么重要：</b>苹果去年推出的iPhone 12 Pro Max是其迄今为止最大的手机。据报道，该公司尚未公布的2021年阵容预计将配备与去年的前身相同的变体，重大变化要到明年才会公布。</blockquote></p><p> <b>Price Action:</b>&nbsp;Apple shares closed 0.2% lower at $133.70 on Wednesday.</p><p><blockquote><b>价格走势：</b>苹果股价周三收盘下跌0.2%，至133.70美元。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/e12ede45502bee1f416acaa08de1af92\" tg-width=\"661\" tg-height=\"250\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A 6.7-Inch iPhone At $900? Analyst Says Apple Will Bring This Product To Market Next Year<blockquote>售价900美元的6.7英寸iPhone？分析师称苹果将于明年将该产品推向市场</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA 6.7-Inch iPhone At $900? Analyst Says Apple Will Bring This Product To Market Next Year<blockquote>售价900美元的6.7英寸iPhone？分析师称苹果将于明年将该产品推向市场</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-06-24 17:14</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Apple Inc</b>(NASDAQ:AAPL) will launch two lower-end iPhones with larger screens next year, as per analyst Ming-Chi Kuo.</p><p><blockquote><b>苹果公司</b>据分析师郭明錤称，（纳斯达克：AAPL）将于明年推出两款屏幕更大的低端iPhone。</blockquote></p><p> <b>What Happened:</b>&nbsp;Apple’s lineup in the second half of 2022 will include two iPhone lines with 6.7-inch screens — one will&nbsp;serve the low-end market and another will cater to the premium one, Kuo said, as per9to5Mac.&nbsp;Both these models will also be available in the 6.1-inch screen size.</p><p><blockquote><b>发生了什么：</b>郭说，苹果在2022年下半年的产品阵容将包括两个6.7英寸屏幕的iPhone系列——一个将服务于低端市场，另一个将迎合高端市场，称为per9to5Mac。这两种型号也将提供6.1英寸的屏幕尺寸。</blockquote></p><p> According to the report, Kuo believes the 2022 lineup will have under-display fingerprint support and it will be available at the most affordable price point for a large screen and expected to be under $900.</p><p><blockquote>根据该报告，Kuo认为2022年的阵容将支持显示下指纹，它将以大屏幕最实惠的价格提供，预计将低于900美元。</blockquote></p><p> The current iPhone lineup includes the 6.7-inch iPhone 12 Pro Max, which is priced at $1,099. Kuo said the 2022 lineup could be named iPhone 14, iPhone 14 Pro, and iPhone 14 Pro Max.</p><p><blockquote>目前的iPhone阵容包括6.7英寸的iPhone 12 Pro Max，售价为1099美元。Kuo表示，2022年的产品阵容可能会被命名为iPhone 14、iPhone 14 Pro和iPhone 14 Pro Max。</blockquote></p><p> <b>Why It Matters:</b>&nbsp;Apple’s iPhone 12 Pro Max, launched last year, is its biggest phone to-date. The company’s yet-to-be-announced 2021 lineup is expected to sport the same variants as its predecessor from last year and the big changes will only be revealed next year, as per reports.</p><p><blockquote><b>为什么重要：</b>苹果去年推出的iPhone 12 Pro Max是其迄今为止最大的手机。据报道，该公司尚未公布的2021年阵容预计将配备与去年的前身相同的变体，重大变化要到明年才会公布。</blockquote></p><p> <b>Price Action:</b>&nbsp;Apple shares closed 0.2% lower at $133.70 on Wednesday.</p><p><blockquote><b>价格走势：</b>苹果股价周三收盘下跌0.2%，至133.70美元。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/e12ede45502bee1f416acaa08de1af92\" tg-width=\"661\" tg-height=\"250\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184361611","content_text":"Apple Inc(NASDAQ:AAPL) will launch two lower-end iPhones with larger screens next year, as per analyst Ming-Chi Kuo.\nWhat Happened: Apple’s lineup in the second half of 2022 will include two iPhone lines with 6.7-inch screens — one will serve the low-end market and another will cater to the premium one, Kuo said, as per9to5Mac. Both these models will also be available in the 6.1-inch screen size.\nAccording to the report, Kuo believes the 2022 lineup will have under-display fingerprint support and it will be available at the most affordable price point for a large screen and expected to be under $900.\nThe current iPhone lineup includes the 6.7-inch iPhone 12 Pro Max, which is priced at $1,099. Kuo said the 2022 lineup could be named iPhone 14, iPhone 14 Pro, and iPhone 14 Pro Max.\nWhy It Matters: Apple’s iPhone 12 Pro Max, launched last year, is its biggest phone to-date. The company’s yet-to-be-announced 2021 lineup is expected to sport the same variants as its predecessor from last year and the big changes will only be revealed next year, as per reports.\nPrice Action: Apple shares closed 0.2% lower at $133.70 on Wednesday.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":1291,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128456309,"gmtCreate":1624528813301,"gmtModify":1631891683991,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586338829912658","idStr":"3586338829912658"},"themes":[],"htmlText":"Apple is the best","listText":"Apple is the best","text":"Apple is the best","images":[{"img":"https://static.tigerbbs.com/036a9e33758775221b0e8c4dc3ad81d8","width":"1125","height":"3231"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128456309","isVote":1,"tweetType":1,"viewCount":2166,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":167545445,"gmtCreate":1624279592087,"gmtModify":1631883985922,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586338829912658","idStr":"3586338829912658"},"themes":[],"htmlText":"Can invest this one ?","listText":"Can invest this one ?","text":"Can invest this one ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167545445","repostId":"1184501396","repostType":2,"repost":{"id":"1184501396","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624267024,"share":"https://www.laohu8.com/m/news/1184501396?lang=zh_CN&edition=full","pubTime":"2021-06-21 17:17","market":"us","language":"en","title":"Orphazyme rose more than 6% in premarket trading<blockquote>Orphazyme盘前交易涨超6%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1184501396","media":"Tiger Newspress","summary":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a c","content":"<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p><p><blockquote>（6月21日）Orphazyme盘前交易涨超6%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>What happened</b></p><p><blockquote><b>发生了什么</b></blockquote></p><p> Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p><p><blockquote>本公司之股份<b>Orphazyme</b>一家处于临床阶段的生物制药公司在食品和药物管理局(FDA)拒绝批准该公司主要候选药物的申请后受到了打击。投资者现在不确定该生物技术公司何时可以获得批准的产品出售，截至中午12点12分，该股股价下跌44.4%。上周五美国东部时间。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p><p><blockquote>FDA去年9月开始审查Orphazyme的主要候选药物arimoclomol的申请，作为一种罕见但危及生命的疾病（称为C型奈曼-皮克病(NPC)）的潜在治疗方法。本月早些时候，由于预期绿灯从未到来，Orphazymes的股价飙升超过200%。</blockquote></p><p> Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p><p><blockquote>该机构没有对arimoclomol做出批准决定，而是以完整回复信(CRL)的形式要求提供更多信息。这让许多刚接触复杂的药物开发领域并预计会出现大规模轧空的投资者感到震惊。</blockquote></p><p> Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p><p><blockquote>许多机构投资者对Orphazyme做空，因为其主要候选药物未能达到支持该申请的关键研究的主要终点。Arimoclomol也未能改善患者在FDA特别要求的次要终点上的评分。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p><p><blockquote>据Orphazyme称，该公司需要进一步证实arimoclomol几乎达到的主要终点的有效性。为了让FDA满意，该公司很可能必须进行一项新的关键研究。</blockquote></p><p> Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p><p><blockquote>一些股东仍然希望欧洲药品管理局不会像FDA那样严格。虽然FDA的欧洲同事过去对罕见疾病的治疗更加宽容，但在产生一些令人信服的临床试验结果之前，arimoclomol可能不会向前推进。</blockquote></p><p> Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p><p><blockquote>尽管缺乏明确的前进道路，但这家总部位于丹麦的公司仍然拥有相当大的市值，按最近的价格计算超过5亿美元。非理性的预期可能会使其居高不下，但对于Orphazyme的任何临床阶段生物技术来说，这都太高了。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme rose more than 6% in premarket trading<blockquote>Orphazyme盘前交易涨超6%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme rose more than 6% in premarket trading<blockquote>Orphazyme盘前交易涨超6%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-06-21 17:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p><p><blockquote>（6月21日）Orphazyme盘前交易涨超6%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>What happened</b></p><p><blockquote><b>发生了什么</b></blockquote></p><p> Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p><p><blockquote>本公司之股份<b>Orphazyme</b>一家处于临床阶段的生物制药公司在食品和药物管理局(FDA)拒绝批准该公司主要候选药物的申请后受到了打击。投资者现在不确定该生物技术公司何时可以获得批准的产品出售，截至中午12点12分，该股股价下跌44.4%。上周五美国东部时间。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p><p><blockquote>FDA去年9月开始审查Orphazyme的主要候选药物arimoclomol的申请，作为一种罕见但危及生命的疾病（称为C型奈曼-皮克病(NPC)）的潜在治疗方法。本月早些时候，由于预期绿灯从未到来，Orphazymes的股价飙升超过200%。</blockquote></p><p> Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p><p><blockquote>该机构没有对arimoclomol做出批准决定，而是以完整回复信(CRL)的形式要求提供更多信息。这让许多刚接触复杂的药物开发领域并预计会出现大规模轧空的投资者感到震惊。</blockquote></p><p> Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p><p><blockquote>许多机构投资者对Orphazyme做空，因为其主要候选药物未能达到支持该申请的关键研究的主要终点。Arimoclomol也未能改善患者在FDA特别要求的次要终点上的评分。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p><p><blockquote>据Orphazyme称，该公司需要进一步证实arimoclomol几乎达到的主要终点的有效性。为了让FDA满意，该公司很可能必须进行一项新的关键研究。</blockquote></p><p> Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p><p><blockquote>一些股东仍然希望欧洲药品管理局不会像FDA那样严格。虽然FDA的欧洲同事过去对罕见疾病的治疗更加宽容，但在产生一些令人信服的临床试验结果之前，arimoclomol可能不会向前推进。</blockquote></p><p> Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p><p><blockquote>尽管缺乏明确的前进道路，但这家总部位于丹麦的公司仍然拥有相当大的市值，按最近的价格计算超过5亿美元。非理性的预期可能会使其居高不下，但对于Orphazyme的任何临床阶段生物技术来说，这都太高了。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184501396","content_text":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.\nSo what\nThe FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.\nInstead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.\nMany institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.\nNow what\nAccording to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.\nSome shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.\nDespite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"tweetType":1,"viewCount":869,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188515238,"gmtCreate":1623454701824,"gmtModify":1631891684004,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586338829912658","idStr":"3586338829912658"},"themes":[],"htmlText":"[Cry]&nbsp;","listText":"[Cry]&nbsp;","text":"[Cry]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/188515238","repostId":"2142858202","repostType":4,"isVote":1,"tweetType":1,"viewCount":1088,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183450283,"gmtCreate":1623343136942,"gmtModify":1631891684017,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586338829912658","idStr":"3586338829912658"},"themes":[],"htmlText":"[Cool]&nbsp;","listText":"[Cool]&nbsp;","text":"[Cool]","images":[{"img":"https://static.tigerbbs.com/5ea4062b862709c77427ce72a351be07","width":"1125","height":"3199"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/183450283","isVote":1,"tweetType":1,"viewCount":1325,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}